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Acquired bleeding disorders encompass a 
heterogeneous group of conditions with 
varied and often complex aetiologies. 
Clinical evaluation of patients presenting 
with a bleeding disorder often provides clues 
as to whether the abnormality resides in 
coagulation factors, platelets or blood vessels. 
A detailed history and complete physical 
examination are therefore imperative for 
meaningful interpretation of laboratory 
tests, as complex haemostatic derangements 
may accompany specific clinical scenarios. 
Interpretation based solely on laboratory 
tests may be misleading. 
For discussion purposes, acquired 
bleeding disorders are divided into 
the following groups: (i) clotting factor 
deficiencies; (ii) abnormalities of platelet 
number or function; (iii) vascular defects; 
or (iv) various combinations of the three 
abovementioned disorders. The last group 
includes liver disease, disseminated intra­
vascular coagulation (DIC) and chronic 
kidney disease. 
Basic laboratory tests (partial thrombo­
plastin time (PTT), international normalised 
ratio (INR), full blood count (with peripheral 
blood smear assessment)) and accurate 
clinical information form a basis for further 
investigations. To this end, an algorithmic 
approach is incorporated to serve as a guide 
(Fig. 1). 
Clotting factor 
deficiencies
Coagulation factor inhibitors
Coagulation factor inhibitors are antibodies 
that neutralise speciﬁc coagulation factors. 
These antibodies can develop against any 
factor in the coagulation cascade, but 
factor VIII (FVIII) is most frequently 
involved, and may develop in patients 
with inherited haemophilia A as an immune 
response to factor­replacement therapy, or 
spontaneously as auto­antibodies, resulting 
in the bleeding condition termed acquired 
haemophilia. The presence of inhibitors 
is suspected in a patient with abnormal 
bleeding without any prior bleeding 
diathesis, or when a patient with known 
haemophilia has more extreme bleeding 
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Fig. 1. Laboratory approach to a suspected acquired bleeding disorder. (LER = leuko-erythroblastic 
blood reaction (signifying possible bone marrow infiltration); INR = international normalised 
ratio; PTT = partial prothrombin time; N = normal; FBC = full blood count; DIC = disseminated 
intravascular coagulation; vit = vitamin; MAHA = microangiopathic haemolytic anaemia; ITP = 
immune thrombocytopenia.) (*Associated with amyloidosis; †Antiphospholipid antibodies usually 
cause thrombosis, not bleeding; however, rare instances of prothrombin deficiency can be associated 
with bleeding; ‡Except for DIC.) 
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than usual or fails to achieve haemostasis after factor replacement. 
Prolongation of the screening clotting assays, i.e. INR and/or PTT, 
with failure to correct on mixing with normal plasma, should alert 
the attending clinician to the presence of an inhibitor. 
Factor inhibitors in inherited haemophilia A and B
This has been discussed in part 1 of this series.[1] 
Acquired haemophilia A 
Acquired haemophilia A (AHA) is a rare (~1 per million of the 
population per year), potentially life­threatening auto­immune 
bleeding disorder due to inhibiting auto­antibodies (inhibitors) 
against endogenous FVIII. Although documented as a rare condition, 
AHA is probably under­diagnosed. Mortality in cases of AHA 
exceeds 20% in patients >65 years of age and those with comorbid 
disease, such as underlying malignancies. Although death directly 
due to excessive bleeding is not common, it does contribute to 
morbidity, thereby increasing the duration and cost of hospitalisation 
(e.g. delayed wound healing and increased transfusion requirements). 
Immune modulation therapy to eradicate the inhibitor also 
contributes significantly to cost and mortality. In contrast to inherited 
haemophilia, AHA affects both males and females and is most 
common in the elderly (median age 64 ­ 78 years). AHA can, 
however, occur in younger patients in relation to pregnancy and 
auto­immune diseases. Most cases are idiopathic, but underlying 
precipitating causes include pregnancy, auto­immune diseases (most 
commonly rheumatoid arthritis), infection, malignancy and drugs 
(e.g. interferon alpha). Research suggests that the breakdown of 
immune tolerance to FVIII is due to both genetic and environmental 
factors. The majority (94.6%) of patients present with bleeding, 
which can either be spontaneous or provoked, e.g. after surgery. 
The site of bleeding is most commonly subcutaneous, followed by 
the gastrointestinal tract, intramuscular sites and genito­urinary 
tract. Bleeding in other sites (intracranial and retroperitoneal) can 
occur, but in contrast to congenital haemophilia, joint bleeding is 
infrequent. Because of the second­order (non­linear) kinetics of 
the anti­FVIII antibodies in AHA, FVIII levels are not predictive of 
bleeding risk and patients can have serious bleeding despite having 
only modestly reduced laboratory­determined FVIII activity levels. 
Inhibitors to other coagulation factors
Inhibitors to other coagulation factors, i.e. fibrinogen, FII, FV, FVII, 
FIX, FX, FXI, FXIII and von Willebrand factor, do occur but are rare. 
Correct identification and quantification are, however, indicated 
for appropriate therapy. As with haemophilia A, these inhibitors 
develop either in patients with congenital deficiencies related to 
exposure to replacement therapy or spontaneously in people without 
a prior bleeding disorder. As with AHA, precipitating factors for 
spontaneous development of inhibitors include infections, drug 
exposure, auto­immune diseases, blood transfusions and underlying 
malignancies.[2]
Diagnosis
Depending on the position of the affected factor in the coagulation 
cascade, the screening assays, i.e. PTT and/or INR, will be prolonged. 
Other causes of prolonged screening tests, such as lupus anticoagulant 
and anticoagulant drugs, e.g. heparin, should be excluded prior to 
identification and quantification of the coagulation factor inhibitor. 
The most common laboratory observation in AHA is a prolonged 
PTT that does not correct with mixing with normal plasma after 
incubation, together with a normal INR, thrombin time and platelet 
count.[2,3]
Management
Management of patients with acquired inhibitors entails: (i) control 
of bleeding with haemostatic agents, as for inherited haemophilia 
patients with inhibitors (part 1);[1] (ii) eradication of the inhibitor 
with immune modulating agents (e.g. corticosteroids and rituximab); 
and (iii) treatment of the underlying pathogenic disease process. 
Thrombotic complications, including myocardial infarctions and 
cerebrovascular accidents, can occur in relation to haemostatic agent 
administration.[2­6]
Vitamin K deficiency
Vitamin K is responsible for gammacarboxylation of FII, FVII, FIX 
and FX, as well as for proteins C, S and Z. Gammacarboxylation 
enables binding to phospholipid membranes via Ca++ bridges. Vita­
min K deficiency is encountered in various clinical scenarios and causes 
include: haemorrhagic disease of the newborn (currently termed vitamin 
K deficiency bleeding), reduced dietary intake, prolonged antibiotic use, 
cholestatic liver disease, malabsorption, and drugs, e.g. anticonvulsants 
and warfarin. The mode of therapy is oral or intravenous vitamin K, and 
patients with severe bleeding are treated with fresh­frozen plasma (FFP) 
or prothrombin complex concentrate (PCC). 
Anticoagulation and antiplatelet agents 
Warfarin
Warfarin, a coumarin derivative, inhibits the enzyme vitamin K 
epoxide reductase and thereby impairs production of vitamin 
K­dependent coagulation factors, i.e. FII, FVII, FIX and FX, as well 
as proteins C, S and Z. Patients treated with coumarin derivatives 
have reduced concentrations of these coagulation factors, with 
consequent increased risk of bleeding that is amplified when the 
INR is supratherapeutic (particularly >5). Other factors that increase 
the bleeding risk include advanced age, a prior history of bleeding, 
previous stroke, hypertension, other drugs associated with a bleeding 
risk (such as non­steroidal anti­inflammatory drugs (NSAIDs)), and 
abnormal liver or renal function. 
Management of warfarin­associated bleeding depends on the 
severity of bleeding, the level of the INR and the indication for 
anticoagulation. For over­warfarinisation without bleeding, stoppage 
of warfarin with possible oral vitamin K administration is usually 
sufficient. However, if this is accompanied by significant bleeding, 
reversal of anticoagulation with factor replacement becomes 
necessary (Table 1).[7]
As for patients scheduled for surgery, anticoagulant reversal must 
be done before surgery to restore normal coagulation status. 
Heparin
Heparin is an anticoagulant that works by binding to and potentiating 
the activity of antithrombin, which then inhibits thrombin. Heparin 
is used for the treatment and prevention of thrombosis. 
High doses of heparin can cause severe bleeding. In this event, 
discontinuation of heparin is usually sufficient owing to its short 
half­life of 8 hours. If rapid reversal of heparin effect is required, 
protamine sulphate is very effective for unfractionated heparin, but 
only reverses ~60% of the antifactor Xa activity of low­molecular­
weight heparin, and has negligible effects on fondaparinux and 
danaparoid (a mixture of anticoagulant glycosaminoglycans used to 
treat heparin­induced thrombocytopenia).[8,9]
Non-vitamin K antagonist oral anticoagulants 
Non­vitamin K antagonist oral anticoagulants (NOACs) include 
thrombin inhibitors, e.g. dabigatran, and FXa inhibitors, e.g. rivaroxaban 
and apixaban. Outcomes of major bleeding are no worse than with 
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vitamin K antagonists. Three NOAC reversal agents are in various stages 
of development, i.e. idarucizumab for thrombin inhibitors, andexanet 
for FXa inhibitors, and ciraparantag for all NOACs.[10]
Antiplatelet agents
Aspirin exerts its antiplatelet effect by irreversibly binding to 
the enzyme cyclo­oxygenase. Other antiplatelet agents include 
NSAIDs and adenosine diphosphate (ADP) receptor inhibitors, 
such as clopidogrel (Plavix). Mild bleeding and bruising may occur 
in response to trauma or surgery, but are likely to be exacerbated 
with coexisting medical conditions, such as haemophilia, renal 
disease and leukaemia. More severe spontaneous bleeds, e.g. from the 
gastrointestinal tract, occur less frequently. The effect of aspirin 
and clopidogrel lasts for 5 ­ 7 days, i.e. the entire lifespan of the 
platelet. 
Abnormalities of platelet number 
Platelet defects are typically associated with mucocutaneous bleeding, 
with the severity depending on the degree of the thrombocytopenia. 
In general, the risk of bleeding is low when platelets are >80 × 109/L, 
and significantly increased when the platelet count is <20 × 109/L 
(where spontaneous bleeding may occur). Platelet transfusion is 
indicated in all bleeding patients to maintain a platelet count of 
50 ­ 100 × 109/L (depending on the site of blood loss), as well as 
in selected patients with a platelet count ˂20 × 109/L as bleeding 
prophylaxis. Causes of thrombocytopenia are divided into: (i) central 
(production failure); and (ii) peripheral (reduced survival). These are 
summarised in Table 2, and some of the more important causes are 
discussed below. 
Immune thrombocytopenia
Immune thrombocytopenia (ITP) is an acquired, auto­immune 
disorder with the formation of antiplatelet antibodies against platelets 
and megakaryocytes, resulting in increased destruction and inadequate 
production of platelets.[11,12]
The term ITP refers to immune thrombocytopenia and no 
longer to the older term idiopathic thrombocytopenic purpura. The 
threshold for ITP and for clinical thrombocytopenia is defined as a 
platelet count <100 × 109/L.[13] 
The incidence of ITP is ~3 ­ 4.5/100  000/year.[14,15] In South 
Africa (SA), primary ITP predominantly affects young females.[16] 
In Europe, however, the median age is 57 years, with a rising inci­
dence with advancing age (>60 years) and a less marked gender 
difference.[14,15]
The presentation of ITP may be acute or insidious. Three phases of 
ITP are recognised: (i) newly diagnosed (0 ­ 3 months from diagno­
sis); (ii) persistent (3 ­ 12 months); and (iii) chronic (>12 months).[13] 
Most adult patients go on to develop chronic ITP. Spontaneous remissions 
occur in 5 ­ 11% of adults, mostly in the first year after diag nosis.[17] 
ITP may be primary (~80% of cases), with no identifiable cause, or sec­
ondary (~20% of cases), due to a number of causes. In SA, a paradigm 
shift has been noted, with an increasing number of patients with 
secondary ITP, largely due to HIV infection.[16] 
Primary ITP is a diagnosis of exclusion. Secondary causes need to 
be excluded, including infections (e.g. HIV), auto­immune disorders 
(e.g. systemic lupus erythematosus), drugs (e.g. rifampicin, quinine 
and heparin), and lymphoproliferative disorders (e.g. chronic 
lymphocytic leukaemia, and lymphoma). In the classic patient 
with primary ITP (young female, isolated thrombocytopenia, no 
abnormalities on the peripheral smear such as fragments or atypical 
cells), a bone marrow aspirate and trephine biopsy (BMAT) is not 
indicated.[18] However, in patients with a suspected secondary cause, 
or in whom the presentation is atypical, or in individuals >60 years of 
age, a BMAT must be performed. 
Patients with ITP may be asymptomatic (where the platelet count is 
usually >30 × 109/L) or may present with bleeding, which is typically 
of the mucocutaneous type. The incidence of major bleeding events, 
such as intracranial haemorrhage and cavity bleeding, is low. The 
platelet count remains the best known predictor of bleeding events 
in ITP. Lymphadenopathy and hepatosplenomegaly are generally not 
encountered in primary ITP and, if present, indicate another cause 
or secondary ITP. 
The decision to initiate treatment is primarily based on whether 
the patient is symptomatic (bleeding) and the level of the platelet 
count (<30 × 109/L). The goal of treatment is to stop the bleeding 
and increase the platelet count to a safe level and not necessarily to 
achieve a normal platelet count. 
Therapeutic agents used in the treatment of ITP are presented in 
Table 3. 
Corticosteroids (CS) are the mainstay of treatment in newly 
diagnosed ITP. Prednisone is the preferred initial treatment. 
Alternative CS include dexamethasone and methylprednisolone. 
Table 1. Management of over-warfarinisation
INR 4.0 ­ 5.0 and no significant bleeding Omit one dose
Decrease weekly dose by ~10 ­ 20% and re­check in 5 ­7 days 
INR 5.0 ­ 9.0 and no significant bleeding Stop warfarin therapy
Oral vitamin K 1.0 ­ 2.5 mg (0.1 ­ 0.25 mL Konakion) if the patient is at high risk of bleeding*
Monitor INR every 2nd day until in therapeutic range
Vitamin K may need to be repeated
Decrease weekly dose of warfarin by 20% once INR therapeutic range has been reached
INR >9.0 and no significant bleeding Stop warfarin therapy
Give oral vitamin K 2.5 ­ 5.0 mg (0.25 ­ 0.5 mL Konakion)*
Vitamin K may need to be repeated
Monitor INR daily until therapeutic range has been reached
Decrease weekly dose of warfarin by 20% once INR is in the therapeutic range
Prolonged INR and significant bleeding Stop warfarin therapy 
Administer PCC 50 U/kg or FFP 15 ­ 20 mL/kg or Bioplasma FDP
Administer vitamin K 1.0 ­ 2.0 mg IVI slowly (can be repeated)
Monitor INR daily
 INR = international normalised ratio; PCC = prothrombin complex concentrate; FFP = fresh­frozen plasma; FDP = freeze­dried plasma; IVI = intravenous infusion.
*Oral vitamin K should be administered with caution to patients with prosthetic heart valves.
162       March 2018, Vol. 108, No. 3
CME
Platelet transfusions are reserved for patients with severe 
thrombocytopenia with active bleeding or recent onset of ‘red 
purpura’, such as oral haemorrhagic bullae. Platelet transfusion is 
not indicated in patients without bleeding, irrespective of the severity 
of the thrombocytopenia.
For emergency treatment, intravenous immunoglobulin (IV Ig) and 
IV/oral CS should be used in combination with platelet transfusions. 
Emergency splenectomy may rarely be necessary in such patients.
For persistent ITP, treatment options include CS and second­line 
immunosuppressive agents (such as azathioprine and mycophenolate 
Table 2. Causes of thrombocytopenia
Spurious (in vitro laboratory artefact)
Platelet clumping
A clotted sample
Reduced survival
Immune thrombocytopenia 
Primary (idiopathic)
Secondary (infection, drugs,*† auto­immune disease, lymphoproliferative disorder)
Micro­angiopathic haemolytic anaemia 
Disseminated intravascular coagulation 
Thrombotic thrombocytopenic purpura 
Haemolytic uraemic syndrome 
HELLP syndrome/pre­eclampsia
Hypersplenism
Production failure
Hypoplastic/aplastic anaemia 
Inherited 
Acquired
Bone marrow infiltration/replacement
Malignancy
Granulomatous inflammation
Myelofibrosis
Ineffective megakaryopoiesis
Vitamin B12 or folic acid deficiency
Drugs, e.g. folate antagonists, such as methotrexate and trimethoprim 
Infection, such as HIV
Myelodysplastic syndrome
Direct megakaryocyte suppression
Drugs, e.g. thiazides, tolbutamide
Alcohol
Viral infection of megakaryocytes, e.g. CMV, HIV 
Thrombopoietin deficiency
Liver disease
HELLP = haemolysis, elevated liver enzymes, low platelets; CMV = cytomegalovirus.
*Including cephalosporins, ciprofloxacin, clarithromycin, fluconazole, penicillins, sulfamethoxazole and vancomycin.
†>50 drugs have been associated with definite evidence of immune­mediated thrombocytopenia.                                
Table 3. Therapeutic agents and dosing schedules employed in the treatment of immune thrombocytopenic purpura in adults
Treatment Agent Dose Duration
First line Prednisone 1 ­ 2 mg/kg/day orally/IVI 2 ­ 3 weeks, then tapered over 4 ­ 6 weeks
Dexamethasone 40 mg/day orally/IVI 4 days
Methylprednisolone 1 g/day IVI 3 days
Immunoglobulin (IV Ig) 1 g/kg/day IVI 
or 400 mg/kg/day
1 ­ 2 days
3 ­ 5 days
Second line Azathioprine 1 ­ 2 mg/kg/day orally Maximum dose 150 mg/day
Mycophenolate mofetil 1 000 mg bid
or 500 mg qid orally
Minimum 4 weeks
Cyclophosphamide 1 ­ 2 mg/kg/day orally Up to or >4 months if necessary
Danazol 200 mg bid up to qid orally At the discretion of the clinician
Vincristine 1 ­ 2 mg IVI weekly Up to a total of 6 mg
Rituximab 375 mg/m2 IVI weekly 4 weeks
Romiplostim 3 ­ 10 mg/kg/week subcutaneously >1 year
IVI = intravenous infusion; IV Ig = intravenous immunoglobulin.
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mofetil) as steroid­sparing drugs. If these prove unsuccessful, 
other second­line agents, such as cyclophosphamide, danazol and 
vincristine, may be considered. Alternative drugs include rituximab 
and thrombopoietin­receptor agonists (TPO­RAs). The choice of 
second­line therapies depends on the experience of the clinician, 
efficacy and safety of the drug, availability, cost and patient preferences.
Chronic ITP refers to disease that continues for >12 months. It 
is likely that the patient has been on intermittent CS and/or other 
immunosuppressive or second­line therapy, with a variable clinical 
response. The three major treatment options for chronic ITP include 
splenectomy, TPO­RAs and rituximab. Each of these options has 
advantages and disadvantages and treatment must be individualised 
to the patient. 
Splenectomy is the most definitive therapy for ITP and is effective 
for persistent and chronic ITP after failure of CS therapy. It is 
recommended that splenectomy be delayed for at least 6 months 
(preferably 12 months) from diagnosis, as there is a chance of 
spontaneous remission in 5 ­ 11% of cases.[17] The overall response 
rate is 70 ­ 90% (complete response 50 ­ 60%, partial response 20 ­ 
30%). The efficacy of open splenectomy and laparoscopic splenectomy 
is similar. However, laparoscopic splenectomy has fewer surgical 
complications, including less postoperative pain, earlier diet tolerance 
and shorter hospital stay. The risk of overwhelming post­splenectomy 
infection is increased 1.4­fold in the first year after the procedure. 
Vaccination against Streptococcus pneumoniae, Neisseria meningitides 
and Haemophilus influenzae is recommended 2 weeks prior to the 
procedure.[19,20] If relapse occurs post splenectomy, accessory splenic 
tissue (splenunculi) should be excluded. In two recent local studies it 
was indicated that splenectomy is beneficial and may be considered 
as the preferred second­line therapy in chronic ITP and failed CS 
therapy, especially in the SA public health sector.[16,21] 
Two TPO­RAs are currently available for use in ITP, romiplostim 
and eltrombopag. These agents are effective in both splenectomised 
and non­splenectomised patients, with a response rate of up to 88%. 
To maintain durable remission, treatment is usually required for 
months to years before discontinuation. Currently, the high cost of 
TPO­RAs prohibits their use in the public health sector.[22,23] 
Rituximab is an anti­CD20 monoclonal antibody, with an off­
label indication in patients with ITP.[24] Remission with rituximab 
occurs in up to two­thirds of patients but is durable in only one­
third. However, the combination of rituximab and high­dose 
dexamethasone has shown a response rate of 71%, with a durable 
remission rate of 57%.[25] A higher risk of infection is anticipated 
with the use of rituximab. 
Locally, there is an increase in secondary ITP, particularly in 
association with HIV.[16,21] The presentation of secondary ITP is 
identical to that of primary ITP, except for an increased likeli­
hood of cytopenias and association of lymphadenopathy and 
hepatosplenomegaly. 
The acute management of secondary ITP is identical to that of 
primary ITP, with the important proviso that the underlying cause be 
specifically treated (e.g. institution of antiretroviral therapy if patients 
are HIV­positive, removal of offending drug). With HIV, there is a 
potentially higher risk of infection, which may be exacerbated by 
immunosuppressive drugs and splenectomy. Although the duration 
to platelet recovery is slower in HIV­seropositive patients with 
ITP, the overall response to treatment is similar to that in the HIV­
negative counterpart.[16] Splenectomy has been shown to be effective 
and safe, irrespective of the HIV status of the patient, and remains an 
appropriate second­line treatment for ITP.[21]
Micro-angiopathic haemolytic anaemia 
Micro­angiopathic haemolytic anaemia (MAHA) encompasses a 
group of entities that are associated with red cell fragmentation 
haemolysis and thrombocytopenia (Table 4). Although MAHA 
may be complicated by thrombocytopenia­related blood loss, the 
risk of bleeding is significantly higher among patients with DIC. 
In contrast, bleeding is an unusual complication in thrombotic 
thrombocytopenic purpura (TTP), despite the thrombocytopenia 
often being very severe (<10 × 109/L). 
DIC is characterised by systemic activation of the coagulation 
cascade with production of microthrombi in the small vessels of 
multiple organs, resulting in organ dysfunction and consumption 
of coagulation factors and platelets.[26] It can manifest with bleeding 
and/or thromboembolism, depending on the rate of fibrinolysis 
and coagulation factor consumption relative to the compensatory 
production of these proteins. Causes of DIC include severe 
sepsis, obstetric calamities, major trauma and some malignancies 
(particularly acute promyelocytic leukaemia). All of these can result 
in systemic coagulation activation, either by exposing procoagulant 
proteins, or by generating procoagulant cytokines. It is diagnosed 
by demonstrating evidence of the following: 
• consumption of blood clotting factors, leading to prolongation 
of the INR and/or PTT, with a decreasing fibrinogen level. 
Fibrinogen is, however, an acute­phase reactant, and is therefore 
not invariably low in patients with DIC
• consumption of anticoagulant molecules (such as antithrombin)
• accumulation of the products of fibrinolysis (such as D­dimers)
• a decreasing platelet count.
The abovementioned factors are diagnostic in an appropriate 
clinical setting. 
Treatment of DIC is aimed at active management of the underlying 
cause, and symptomatic management of the associated organ and 
coagulation abnormalities. Treatment options include FFP and 
platelet transfusions in the event of bleeding, or low­molecular­
weight heparin therapy when thromboembolic phenomena 
predominate. The use of antifibrinolytic agents is generally not 
advised owing to the risk of exacerbation of the microvascular 
thrombotic process, but may be of benefit in patients with 
hyperfibrinolysis (typified by very low fibrinogen and markedly 
elevated D­dimer levels). The mortality rate associated with DIC is 
high, particularly in the presence of pronounced organ dysfunction 
or severe coagulopathy. 
Organ dysfunction
Liver disease
Coagulopathy in patients with liver disease can be difficult to 
differentiate from laboratory­determined DIC values. Haemostatic 
abnormalities due to liver disease include:
• thrombocytopenia due to thrombopoietin deficiency, hyper­
splenism (if enlarged spleen) and possible megakaryocytic 
suppression (secondary to alcohol or hepatitis B or C infection)
• coagulopathy due to impaired production of clotting factors by 
the liver, vitamin K deficiency (e.g. alcohol abuse, obstructive 
jaundice), production of functionally abnormal fibrinogen 
(dysfibrino genaemia)
• increased fibrin degradation products due to: (i) impaired hepatic 
clearance; and/or (ii) hyperfibrinolysis (impaired clearance 
of tissue plasminogen activator and decreased production of 
fibrinolytic inhibitors).
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As there is a concomitant depletion of both pro­ and anticoagulant 
molecules in patients with synthetic dysfunction of the liver, bleeding 
manifestations are often not as severe as would be anticipated from 
the degree of the laboratory derangements. However, associated renal 
dysfunction or infection can predispose to bleeding. In particular, 
gastrointestinal bleeding from oesophageal varices is a concern in 
patients with portal hypertension, requiring reduction of the portal 
pressure and ligation of the varices. Coagulation factor, fibrinogen 
and platelet replacement therapy may be needed, but caution should 
be exercised against liberal use of FFP in liver disease, as the 
plasma volume expansion may elevate portal pressure and thereby 
paradoxically increase the risk of variceal bleeding.[27] Bleeding due 
to hyperfibrinolysis, diagnosed with viscoelastic tests such as the 
thromboelastogram (TEG), can respond to antifibrinolytic agents, 
e.g. tranexamic acid. 
Renal disease
Numerous haemostatic disturbances are observed in renal disease, 
which may predispose to a hypo­ or hypercoagulable state. There is 
no superior pathogenic factor to determine whether a patient would 
be prone to bleeding or thrombosis, where the dynamics of events are 
often influenced by comorbid factors.[28] Tendency to bleed is caused 
by platelet dysfunction (due to accumulation of toxic metabolites, 
fibrinogen degradation products, anaemia, drugs, etc.) and decreased 
FXI/XII level. Desmopressin and/or antifibrinolytics are generally 
effective in controlling uraemic bleeding. 
Vascular defects
Acquired vascular bleeding disorders include the following: 
Scurvy. Vitamin C promotes peptidyl hydroxylation of procollagen, 
and its deficiency causes abnormal collagen formation with defective 
perivascular support. This predisposes to capillary fragility and 
mucocutaneous bleeding. Treatment is with vitamin C 200 mg daily.
Henoch-Schönlein purpura. This idiopathic disorder is primarily a 
disease of children, but may occur at any age, and is characterised by 
abdominal colic, arthritis, nephritis and palpable purpura. Biopsy of 
the skin shows an acute immune­related vasculitis and complement/
immunoglobulin complexes. Treatment entails supportive care and 
steroids in more severe cases.
Paraproteinaemia and amyloidosis. The mechanism of bleeding is 
multifactorial, including interference with coagulation factor levels/
function, impaired platelet aggregation and deposits of light chain/
amy loid fibrils in cutaneous blood vessels, with increased vessel 
fragility. Cryoglobulins may similarly deposit in dermal vessels and 
cause vasculitis and purpura. Management entails treatment of the 
underlying condition.
Senile purpura. In the elderly there is loss of subcutaneous collagen 
and elastin fibres. Bruising is usually induced by minor trauma.
Table 4. Summary of common microangiopathic haemolytic anaemias
Microangiopathic entity Common features Causal/risk factors Management
Disseminated intravascular 
coagulation
Anaemia and 
thrombocytopenia
Red cell fragmentation
Deranged coagulogram 
 (↑ INR and/or PTT, ↑ D­dimers, 
↓ fibrinogen and AT levels)
Major trauma
Severe infection/sepsis
Obstetric accidents
Select malignancies
Transfusion reaction
Giant haemangiomas
Liver disease
Treat underlying cause
LMWH in early stages* 
Platelet/FFP/cryoprecipitate 
infusion if bleeding
Thrombotic 
thrombocytopenic purpura 
Severe anaemia and thrombocytopenia
Marked red cell 
fragmentation
± renal impairment
± fever
± fluctuating neurological 
manifestations
ADAMSTS13 levels may be low
HIV infection
Auto­immune disease
Drugs (clopidogrel, 
ticlodipine, quinine)
Metastatic adenocarcinoma
Allogeneic stem cell/solid­organ 
transplantation
Congenital deficiency of ADAMTS13 
(rare)
Plasma exchange/infusion
Corticosteroids
Treat underlying cause 
Platelet transfusion C/I 
unless bleeding
Haemolytic uraemic 
syndrome
++ Red cell fragmentation
Marked renal impairment
Moderate anaemia and 
thrombocytopenia
C’3 and C’4 levels may be low in 
aHUS
Shiga toxin­associated diarrhoeal illness
  Shigella dysenteriae 
  Escherichia coli 
  (O157:H7 & O104:H4)
aHUS dysregulation of alternate 
C’ pathway
Congenital factor H or I deficiency/
antibodies to factor H 
Supportive measures
A trial of plasma exchange 
(aHUS)
Eculizumab (aHUS) 
(limited availability) 
Dialysis – usually
for aHUS
HELLP syndrome/pre­
ecclampsia
Anaemia and 
thrombocytopenia
Red cell fragments
Raised AST/ALT 
Hypertension
Headache and visual disturbance, 
RUQ pain, pulmonary oedema
Risk of recurrence in 
subsequent pregnancies
Emergency delivery
by caesarean section
aHUS = atypical haemolytic uraemic syndrome; RUQ = right upper quadrant; INR = international normalised ratio; PTT = partial thromboplastin time; LMWH = low­molecular­weight 
heparin; AT = antithrombin; HELLP = haemolysis/elevated liver enzymes/low platelet count; ++ = moderate to severe; + = mild to moderate; FFP = fresh­frozen plasma; AST = aspartate 
transaminase; ALT = alanine transaminase; C’ = complement; C/I = contraindicated.
*Particularly useful if the dominant clinical manifestations are thrombotic.
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Conclusion
Acquired bleeding disorders encompass a heterogeneous group of 
conditions with varied aetiologies. A detailed history and complete 
physical examination are imperative for meaningful interpretation 
of laboratory tests and appropriate treatment. Bleeding is often a 
presenting manifestation of systemic disease and therefore necessitates 
a multidisciplinary team approach. 
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